Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

(2019) Cristina Scarpazza et al.   NEUROLOGICAL SCIENCES

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

(2019) Frederik Barkhof et al.   NEUROLOGY

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

(2019) Marinella Clerico et al.   Neurotherapeutics

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event

(2018) Joseph R. Berger et al.   JOURNAL OF NEUROVIROLOGY

Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder

(2018) Su-Hyun Kim et al.   NEUROCHEMISTRY INTERNATIONAL

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

(2017) Tatiana Plavina et al.   NEUROLOGY

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY